Aviado · Research
Longevity Daily
Friday, April 17, 2026
Listen
Today's Brief
Today's lead is a landmark Cochrane review putting Alzheimer's anti-amyloid drugs on trial: seven "breakthrough" treatments clear plaques but deliver no meaningful cognitive benefit, challenging billions in drug development and recent FDA approvals. The gut-brain axis dominates two other strong stories — new research linking diverse gut microbiomes to better stress resilience, and earlier findings connecting IBS and vitamin D deficiency to Parkinson's risk more than a decade before diagnosis. Lifespan.io reports that vitamin C counters iron-driven cellular aging in primates, while separate research identifies a "cell death" protein quietly aging blood stem cells. Bryan Johnson's Blueprint also enters the biomarker testing market with a $365 consumer platform, competing directly with Function Health.
10 stories8 peer-reviewed
Cognitive Health & Neuroprotection
Cochrane Review: 'Breakthrough' Alzheimer's Drugs Clear Plaques — But Deliver No Meaningful Benefit
A comprehensive Cochrane meta-analysis of seven monoclonal antibody drugs designed to clear amyloid plaques from Alzheimer's patients' brains has concluded their clinical benefit is "well below" what would matter to patients or caregivers. The drugs successfully reduce amyloid — but that reduction doesn't appear to translate into meaningful improvements in cognition or daily function, effectively challenging the foundational assumption that clearing plaques reverses disease. This landmark review sparks a long-overdue reckoning with billions spent on a drug class that has dominated Alzheimer's research for two decades, including recently approved treatments like lecanemab and donanemab. If you're navigating this space for a loved one, the message is stark: amyloid clearance alone is not the answer.
Read more →IBS and Vitamin D Deficiency Linked to Parkinson's Risk — More Than a Decade Before Diagnosis
Researchers tracking longitudinal health data found that IBS, vitamin D deficiency, and B vitamin deficiencies appear in patients more than ten years before a Parkinson's diagnosis — suggesting these gut and nutritional disruptions may be early upstream signals, not coincidental comorbidities. The gut-brain axis is front and center: compromised intestinal function and oxidative stress from nutrient deficits may fuel the neurodegeneration that leads to Parkinson's over time. If you're already monitoring vitamin D levels, this adds a neuroprotective urgency to keeping them in a healthy range well before any neurological symptoms emerge.
Read more →A More Diverse Gut Microbiome Produces a Stronger, More Flexible Stress Response
A new human study finds that higher gut microbial diversity correlates with a more robust and adaptable physiological response to acute stress, mediated in part by bacterial metabolites like butyrate and propionate. This gut-brain axis finding suggests your microbiome isn't just a digestion story — it's actively shaping how your nervous system handles pressure and recovers from it. Translation: fiber-rich, diverse diets that nourish a varied gut ecosystem may offer a meaningful buffer against stress-related cognitive wear over time.
Read more →Supplements & Compounds
Vitamin C Counters Iron-Driven 'Ferro-Aging' in Primate Study
Researchers working with cynomolgus monkeys have described a process called "ferro-aging" — in which age-related iron accumulation triggers oxidative damage and cellular senescence — and found that vitamin C supplementation can meaningfully delay this cascade. This is among the first primate studies to directly link iron dysregulation to aging biology and test a nutritional countermeasure in a species close to humans. Caveat: this is an animal study, dose and form of vitamin C matter, and human clinical evidence remains limited — but it strengthens the mechanistic case for monitoring iron levels alongside your antioxidant intake.
Read more →Neuriva Brain Supplement: What the Evidence Actually Says
Pharmacy Times takes a rigorous look at Neuriva, the widely sold brain supplement claiming to support memory, focus, and concentration — in part through celebrity endorsements. The review finds that while key ingredients like phosphatidylserine and coffee fruit extract have some research behind them, the clinical evidence is limited, studies are often industry-funded, and the FDA has not evaluated the brand's efficacy claims. If Neuriva is in your stack, the honest verdict is that it's unlikely to harm you — but the science doesn't yet support the marketing.
Read more →Research & Papers
A 'Cell Death' Protein Is Quietly Aging Your Blood Stem Cells
Scientists have identified a protein called MLKL — previously known for triggering a form of inflammatory cell death called necroptosis — as a key driver of blood stem cell aging, specifically by damaging mitochondria in hematopoietic stem cells over time. When researchers deactivated the MLKL pathway, blood stem cells retained significantly more youthful function, pointing to a potential therapeutic target for preserving immune vitality with age. This is early-stage preclinical work, but it adds a compelling new entry to the growing list of mitochondrial damage mechanisms driving immunosenescence.
Read more →Men and Women Age Immunologically Along Strikingly Different Paths
A detailed new assessment of sex-based differences in immune system aging finds that men and women diverge substantially in how specific immune cell populations shift over time — mapping the cellular specifics onto a pattern already visible at the macro level (women live longer; men face earlier mortality from infection and cancer). The findings carry potential implications for personalized longevity interventions and sex-specific immunological therapies. Practical applications remain distant, but this kind of granular characterization is the necessary groundwork.
Read more →Suppressing the Hunger Hormone Receptor Fights Muscle Loss in Aging Mice
Published in Aging Cell, new research shows that suppressing the receptor for ghrelin — the appetite-stimulating "hunger hormone" — improves muscle function and combats sarcopenia in older mice. Ghrelin has documented negative effects on muscle preservation, and blocking its receptor appeared to shift the metabolic balance toward muscle maintenance and strength. This is a mouse study, but it adds a novel hormonal angle to the sarcopenia research field and could eventually inform drug targets for age-related muscle loss.
Read more →Lifestyle & Nutrition
What You Eat Rewrites Your Epigenome — A New Review Maps the Evidence
A comprehensive review from Nanjing University researchers documents how dietary patterns — including caloric restriction, Mediterranean-style eating, and specific micronutrients — directly alter DNA methylation and histone modifications in ways associated with slower biological aging. This epigenetic framing bridges the familiar "eat well" message with a molecular mechanism: your food choices are sending active instructions to your genome, not just fueling your metabolism. The review reinforces evidence already popular in the longevity community while acknowledging that most findings remain observational and that translation to human longevity outcomes needs more RCT validation.
Read more →Industry & Policy
Bryan Johnson's Blueprint Enters Consumer Biomarker Testing With $365 Platform
Bryan Johnson's longevity company Blueprint has launched a direct-to-consumer biomarker testing platform priced at $365, entering a competitive space alongside Function Health and others racing to make comprehensive blood panel testing mainstream. The move brings a high-profile celebrity brand into the category, which could accelerate adoption among the broader wellness audience. Whether Blueprint's platform offers analytical depth and clinical guidance beyond its competitors — or is primarily a brand extension — remains to be tested by early users.
Read more →